Selvita announced that at the Shareholder Meeting of the Company which took place on Sep. 19, 2019, shareholders have adopted a resolution to approve the plan to separate the Selvita oncology therapeutics and contract research business units into two independent companies. The Selvita contract research company will be led by Boguslaw Sieczkowski, MBA, as Chief Executive Officer, with Milosz Gruca, Ph.D., as Executive VP and Director of Biology; Miroslawa Zydron, Ph.D., as Director of Contract Chemistry; Edyta Jaworska, MBA, as Head of Integrated Drug Discovery; Dawid Radziszewski LL.M as Head of Legal; and Dariusz Kurdas as Chief Financial Officer.

The supervisory board for the Selvita contract research company will consist of Piotr Romanowski (Chairman), Tadeusz Wesolowski, Rafal Chwast, Wojciech Chabasiewicz, Partner at Chabasiewicz, Kowalska and Partners, L.P. Jacek Osowski, MBA, CFA, investment advisor, and Pawel Przewiezlikowski.